Intrinsic Value of S&P & Nasdaq Contact Us

Sight Sciences, Inc. SGHT NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.67
+153.1%

Sight Sciences, Inc. (SGHT) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 4 Buy, 4 Hold, 1 Sell.

The consensus price target is $9.67 (low: $8.00, high: $12.00), representing an upside of 153.1% from the current price $3.82.

Analysts estimate Earnings Per Share (EPS) of $-0.96 and revenue of $0.08B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-1.03 vs est $-0.96 (missed -6.8%). 2025: actual $-0.74 vs est $-0.73 (missed -0.9%). Analyst accuracy: 96%.

SGHT Stock — 12-Month Price Forecast

$9.67
▲ +153.14% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Sight Sciences, Inc., the average price target is $9.67, with a high forecast of $12.00, and a low forecast of $8.00.
The average price target represents a +153.14% change from the last price of $3.82.
Highest Price Target
$12.00
Average Price Target
$9.67
Lowest Price Target
$8.00

SGHT Analyst Ratings

Buy
9
Ratings
4 Buy
4 Hold
1 Sell
Based on 9 analysts giving stock ratings to Sight Sciences, Inc. in the past 3 months
Rating breakdown
Buy
4 44%
Hold
4 44%
Sell
1 11%
44%
Buy
4 analysts
44%
Hold
4 analysts
11%
Sell
1 analysts

EPS Estimates — SGHT

96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$1.03 vs Est –$0.96 ▼ 6.4% off
2025 Actual –$0.74 vs Est –$0.73 ▼ 0.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — SGHT

100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.080B vs Est $0.080B ▼ 0.2% off
2025 Actual $0.077B vs Est $0.077B ▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message